Julie Iwashita
Chief Tech/Sci/R&D Officer at CONTINEUM THERAPEUTICS, INC.
Profile
Julie Iwashita is currently the Vice President of Clinical Operations at Cirius Therapeutics, Inc. and the Vice President-Clinical Operations at Contineum Therapeutics, Inc. She previously held positions as the Senior Director-Clinical Development at MAP Pharmaceuticals LLC from 2009 to 2011, the Executive Director-Clinical Operations at Sorbent Therapeutics, Inc. from 2011 to 2014, the Senior Director-Clinical Development at Affymax, Inc. from 2004 to 2008, the Senior Director-Clinical Operations at Proteolix, Inc. from 2008 to 2009, the Executive Director-Clinical Development at Laguna Pharmaceuticals, Inc. from 2014 to 2015, and the Executive Director-Clinical Operations at Kodiak Sciences, Inc. from 2016 to 2017.
Ms. Iwashita obtained her undergraduate degree from Stanford University.
Julie Iwashita active positions
| Companies | Position | Start |
|---|---|---|
| CONTINEUM THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2020-09-30 |
Cirius Therapeutics, Inc.
 Cirius Therapeutics, Inc. BiotechnologyHealth Technology Cirius Therapeutics, Inc. operates as a biotechnology company. It offers metabolic treatment for nonalcoholic steatohepatitis. The company was founded by Jerry R. Colca and Brian Finck and was founded in March 2017, and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | - |
Former positions of Julie Iwashita
| Companies | Position | End |
|---|---|---|
| KODIAK SCIENCES INC. | Chief Tech/Sci/R&D Officer | 2017-03-31 |
Laguna Pharmaceuticals, Inc.
 Laguna Pharmaceuticals, Inc. BiotechnologyHealth Technology Laguna Pharmaceuticals, Inc. develops and manufactures biopharmaceutical products. Its lead product, Vanoxerine is a therapeutic candidate being developed for treatment of atrial fibrillation and atrial flutter. The firm’s product is a potential pharmaceutical option to rapidly terminate atrial fibrillation in both hospital and home settings. The company was founded in 2006 by Arthur M. Brown and Howard C. Dittrich and is headquartered in Cleveland, OH. | Corporate Officer/Principal | 2015-10-31 |
Sorbent Therapeutics, Inc.
 Sorbent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sorbent Therapeutics, Inc. develops therapies for cardiovascular and renal diseases. It focuses on the development of non-absorbed polymeric drugs to satisfy unmet clinical needs in large cardiovascular and renal markets such as heart failure, chronic kidney disease and hypertension. The company was founded by William R. Rajski, Dean Abrassart, Donald W. Joseph and Lee W. Henderson on January 25, 2005 and is headquartered in Sunnyvale, CA. | Corporate Officer/Principal | 2014-06-30 |
MAP Pharmaceuticals LLC
 MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | Chief Tech/Sci/R&D Officer | 2011-01-31 |
Proteolix, Inc.
 Proteolix, Inc. Pharmaceuticals: MajorHealth Technology Proteolix, Inc. manufactures bio-pharmaceutical related products. It engages in the discovery, development, and marketing of pharmaceutical products to treat cancer and immunological conditions. The company was founded by Susan M. Molineauxf in December 2003 and is headquartered in South San Francisco, CA | Chief Tech/Sci/R&D Officer | 2009-09-30 |
Training of Julie Iwashita
| Stanford University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| KODIAK SCIENCES INC. | Health Technology |
| AFFYMAX, INC. | Health Technology |
| CONTINEUM THERAPEUTICS, INC. | Health Technology |
| Private companies | 5 |
|---|---|
Sorbent Therapeutics, Inc.
Sorbent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sorbent Therapeutics, Inc. develops therapies for cardiovascular and renal diseases. It focuses on the development of non-absorbed polymeric drugs to satisfy unmet clinical needs in large cardiovascular and renal markets such as heart failure, chronic kidney disease and hypertension. The company was founded by William R. Rajski, Dean Abrassart, Donald W. Joseph and Lee W. Henderson on January 25, 2005 and is headquartered in Sunnyvale, CA. | Health Technology |
Laguna Pharmaceuticals, Inc.
Laguna Pharmaceuticals, Inc. BiotechnologyHealth Technology Laguna Pharmaceuticals, Inc. develops and manufactures biopharmaceutical products. Its lead product, Vanoxerine is a therapeutic candidate being developed for treatment of atrial fibrillation and atrial flutter. The firm’s product is a potential pharmaceutical option to rapidly terminate atrial fibrillation in both hospital and home settings. The company was founded in 2006 by Arthur M. Brown and Howard C. Dittrich and is headquartered in Cleveland, OH. | Health Technology |
Cirius Therapeutics, Inc.
Cirius Therapeutics, Inc. BiotechnologyHealth Technology Cirius Therapeutics, Inc. operates as a biotechnology company. It offers metabolic treatment for nonalcoholic steatohepatitis. The company was founded by Jerry R. Colca and Brian Finck and was founded in March 2017, and is headquartered in San Diego, CA. | Health Technology |
MAP Pharmaceuticals LLC
MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | Health Technology |
Proteolix, Inc.
Proteolix, Inc. Pharmaceuticals: MajorHealth Technology Proteolix, Inc. manufactures bio-pharmaceutical related products. It engages in the discovery, development, and marketing of pharmaceutical products to treat cancer and immunological conditions. The company was founded by Susan M. Molineauxf in December 2003 and is headquartered in South San Francisco, CA | Health Technology |
- Stock Market
- Insiders
- Julie Iwashita
